Madam Speaker, the opioid and toxic drug supply crisis is heartbreaking and has taken a tragic toll on the families, loved ones and communities of those we have lost across Canada. I would like to thank the member for Courtenay—Alberni for his advocacy on this critical issue and for prompting this important debate in the House of Commons.
The Government of Canada recognizes that the overdose crisis is one of the most serious public health threats in Canada's recent history. This unprecedented crisis is having devastating effects on people, friends and families, as well as on communities across the country.
Unfortunately, the most recent national data shows that there were 26,690 apparent opioid toxicity deaths between January 2016 and September 2021. Fentanyl and its analogues continue to be the primary causes of the crisis. Up to 86% of accidental apparent opioid toxicity deaths over the first nine months of 2021 are tied to fentanyl.
Our government recognizes that problematic substance use is, first and foremost, a public health issue. Since 2017, our government has moved forward with significant action, investing over $800 million to address the overdose crisis and substance use-related issues. We have improved access to treatment and harm reduction, improved access to a safer supply, reduced regulatory barriers to treatment, strengthened law enforcement, developed educational products and tools for health care providers, as well as the public, and advanced research and surveillance to build the evidence base.
These key investments include $282 million for the substance use and addictions program, which provides grants and contributions to other levels of government and to community organizations in order to address the illegal supply of toxic drugs and substance use issues.
Treatment is an essential way to help people struggling with problematic substance use who want to stop using drugs and live a healthier life. We have invested $200 million over five years, with $40 million ongoing each year, to improve the delivery of culturally adapted substance use treatment and prevention services in first nations communities.
Our government has also provided one-time funding of $150 million to the provinces and territories through the emergency treatment fund in order to improve access to evidence-based treatment services. The provinces and territories are also contributing an amount matching the federal funding beyond the first $250,000.
The evidence clearly shows that harm reduction measures save lives. Since 2017, supervised consumption sites in Canada have received more than 3.3 million visits and reversed almost 35,000 overdoses without a single death at a site. These sites also provide access to supportive and trusted relationships for people who use drugs, including opportunities to access treatment.
These sites made more than 148,000 referrals to social services and health care services. Since January 1, 2016, our government has increased the number of approved supervised consumption sites from one to 38. We also increased access to naloxone, a life-saving medication, including in remote and isolated indigenous communities.
Improving the safe supply will also be critical to saving lives, and we are investing more than $63 million to extend access to a safe supply of pharmaceutical-grade alternatives.
Treating addiction as a public health issue means we are also committed to diverting people who use drugs away from the criminal justice system and toward supportive and trusted relationships in health and social services.
In December 2021, the Minister of Justice and Attorney General of Canada introduced Bill C-5, an act to amend the Criminal Code and the Controlled Drugs and Substances Act. Among other measures, the bill would have the police and prosecutors consider alternative measures, including diverting individuals to treatment programs, giving a warning or taking no further action, instead of laying charges or prosecuting individuals for simple drug possession.
Our government also facilitated the passage of the Good Samaritan Drug Overdose Act in May 2017.
In August 2020, the Public Prosecution Service of Canada released guidelines for prosecutors indicating that alternatives to criminal prosecution should be considered for simple possession for personal use, unless there are serious aggravating factors.
We also recognize the different approaches that cities, provinces, territories and other organizations are taking to address the opioid crisis, including how they are approaching the potential decriminalization of personal possession in their communities. We continue to work with these partners, many who are pursuing comprehensive, regional decriminalization proposals for their jurisdictions.
The Controlled Drugs and Substances Act generally prohibits such activities, including personal possession of controlled substances, unless those activities have been specifically authorized through regulations or an exemption under the act. Section 56 of the Controlled Drugs and Substances Act gives the minister broad powers to exempt people for controlled substances from the application of any of the provisions of the act for medical or scientific purposes or if otherwise in the public interest. Currently, the federal government is reviewing requests for section 56 exemptions for the decriminalization of simple possession from the Province of British Columbia, the City of Vancouver and Toronto Public Health.
This private member's bill, Bill C-216, proposes to immediately decriminalize personal possession of controlled substances across Canada without addressing the complex issues of implementation. This does raise significant concerns. Decriminalization of the personal possession of illicit drugs at the national level requires a comprehensive and well-thought-out, multi-jurisdictional strategy around implementation. This includes ensuring adequate and appropriate health and social services resources; engagement, additional training and guidance of law enforcement; specific definitions of personal possession; public education and awareness strategies; as well as meaningful consultations with indigenous governments, partners and organizations.
Our government will ensure that these decisions are based on evidence and applied research. In getting this right, effective indicators, data and evaluation will be important to inform our approach going forward.
Other jurisdictions are evaluating evidence-based approaches, and we are working with our partners to find innovative solutions.
The mandate letter of the Minister of Mental Health and Addictions and Associate Minister of Health calls on the minister to advance a comprehensive strategy to address prohibitive substance use in Canada, support efforts to improve public education to reduce stigma, support provinces and territories, work with indigenous communities to provide access to a full range of evidence-based treatment and harm reduction, and create standards for substance use treatment programs.
We know that more must be done, and we will continue to work with the provinces and territories, experts, stakeholders, people with real-life experiences and local communities to put an end to this strategy.
Our government will use all the tools at its disposal to put an end to this public health crisis.
